KALA BIO, Inc
KALA BIO, Inc. is a U.S.-based clinical-stage ophthalmology company focused on developing biologic therapies for serious eye diseases. Its current pipeline centers on KPI-012 for persistent corneal epithelial defect (PCED) and KPI-014 for other ocular indications, following the 2022 sale of its commercial eye-care business to Alcon.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueKPI-012 is the company’s main therapeutic asset being developed for PCED and potentially other ocular indications.
KPI-014 includes early-stage research aimed at expanding the company’s ophthalmology pipeline.
MSC-S is the underlying cell-based/biologic platform used to generate ophthalmic product candidates.
Customers
KALA BIO does not currently sell commercial products; its near-term customers would be ophthalmologists, eye-care specialists, and the patients they treat if KPI-012 is approved. The company also depends on third-party payors and government reimbursement systems, because coverage and pricing will shape adoption in the U.S. and abroad.
Would prescribe KPI-012 if approved for PCED or related ocular indications, based on clinical efficacy and ease of use.
End users of the therapy; demand is driven by unmet need in difficult-to-heal corneal disease.
Commercial and government payors would determine access through coverage, pricing, and reimbursement.
Potential collaborators for distribution, co-promotion, or licensing in non-U.S. markets.
Strategy
KALA BIO’s strategy is to advance KPI-012 through clinical development, secure regulatory approval, and then commercialize it either directly in the U.S. or through partnerships. Near term, the company is also focused on preserving liquidity, exploring strategic alternatives, and raising capital to fund operations and development.
The company’s value depends on generating clinical data that can support approval and future commercialization.
Management disclosed substantial doubt about going concern and the need for new capital to continue operations.
If approved, the company needs sales, marketing, distribution, and reimbursement capabilities to launch successfully.
Geography
The company is headquartered in the United States and expects initial commercialization efforts, if approved, to be centered there with a small targeted sales force. Management has also indicated it may pursue select non-U.S. markets through partners, which would reduce direct operating footprint but also lower economics versus self-commercialization.
Risks
KALA BIO faces the classic risks of a development-stage biotech company, including clinical failure, regulatory delay, reimbursement uncertainty, and heavy dependence on external financing. The company also disclosed acute liquidity and going-concern pressure, making capital access and strategic alternatives especially important to its near-term survival.
- Going-concern and liquidity riskImpact: CriticalLikelihood: High
Management stated existing resources are not expected to fund operations for at least twelve months.
Exposure: Corporate funding and operations
- Clinical development failure or delayImpact: HighLikelihood: High
KPI-012 must show favorable results before approval and commercialization can occur.
Exposure: KPI-012 and future ocular programs
- Dependence on third-party financing and strategic transactionsImpact: HighLikelihood: High
The company may need equity, debt, partnerships, or asset sales to continue as a going concern.
Exposure: Balance sheet and strategic flexibility
- Commercialization and reimbursement riskImpact: HighLikelihood: Medium
Even if approved, the company may struggle to obtain coverage, pricing, and clinician adoption.
Exposure: U.S. launch and ex-U.S. partnering
- Intellectual property and patent challengesImpact: MediumLikelihood: Low
Biotech value depends on protecting candidate and platform rights from third-party claims.
Exposure
Accounting
Judgemental itemsManagement disclosed substantial doubt about funding operations for at least twelve months.
Impact: May affect liquidity disclosures, financing assumptions, and investor assessment of survival
The CIRM award is accounted for as a research and development contract, not customer revenue.
Impact: Grant income is matched to R&D expense timing
Warrants, embedded derivatives, and contingent consideration require periodic remeasurement.
Impact: Can create non-cash volatility in earnings
Employee and director equity awards are a recurring expense for a development-stage biotech.
Impact: Affects operating loss and diluted share count analysis
Future tax benefits depend on uncertain profitability and utilization of losses.
Impact: May materially affect reported tax expense and equity
Similar listed companies
Publicly listed companies with a comparable business focus.
Korro Bio, Inc.
KRRO · Pharmaceutical Preparations
Kiora Pharmaceuticals, Inc
KPHMW · Pharmaceutical Preparations
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026